NYSE · WST

West Pharmaceutical Services, Inc.

$331.25 +$3.05 (+0.93%) 1D After hours
Charting by TradingView

Key Metrics

$23.10B
Market cap
42.56×
P/E · TTM
$3.22B
Revenue · TTM
$542.70M
Net income
EPS · TTM $7.43
Dividend yield 0.3%
Free cash flow $458.00M
Beta · 1Y 0.67
EBITDA · TTM $831.60M
Gross margin 36.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 23
    The stock moved +12.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 23

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$23.10B
Enterprise value$22.78B
Shares outstanding70.4M
52-wk range$223.83 – $386.00
Avg volume · 20D572.7K
Net cash $318.60M
Book value / share$40.96
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About West Pharmaceutical Services, Inc.
IPO dateJan 2, 1973
Employees10800

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E42.56
P/S7.17
P/FCF50.43
EV/EBITDA27.39
EV/Sales7.07
Graham №$82.78

Profitability

Gross 36.3%
Operating 20.3%
Net 16.8%
FCF 14.2%
ROE / ROIC 19.1% · 19.3%

Financial Health

Current ratio2.71
Quick ratio2.04
Debt / equity0.07
Debt / EBITDA 0.24Low leverage
Net cash $318.60M
Working capital$1.15B

Cash Flow · TTM

Operating CF $715.30M
Capex −$257.30M
Free cash flow $458.00M
Buybacks $298.10M
Dividends paid $61.80M
Shareholder yield 1.6%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

15.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$82.78 vs $331.25
Trades 4.0× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings